CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide von Gurney, Mark, Stikvoort, Arwen, Nolan, Emma, Kirkham-McCarthy, Lucy, Khoruzhenko, Stanislav, Shivakumar, Rama, Zweegman, Sonja, Van de Donk, Niels W C J, Mutis, Tuna, Szegezdi, Eva, Sarkar, Subhashis, O'Dwyer, Michael

Volltext

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond von van de Donk, Niels W. C. J., Janmaat, Maarten L., Mutis, Tuna, Lammerts van Bueren, Jeroen J., Ahmadi, Tahamtan, Sasser, A. Kate, Lokhorst, Henk M., Parren, Paul W. H. I.

Volltext

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization von Drent, Esther, Themeli, Maria, Poels, Renée, de Jong-Korlaar, Regina, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C.M., Zweegman, Sonja, van de Donk, Niels W.C.J., Groen, Richard W.J., Lokhorst, Henk M., Mutis, Tuna

Volltext

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma von Nijhof, Inger S., Casneuf, Tineke, van Velzen, Jeroen, van Kessel, Berris, Axel, Amy E., Syed, Khaja, Groen, Richard W.J., van Duin, Mark, Sonneveld, Pieter, Minnema, Monique C., Zweegman, Sonja, Chiu, Christopher, Bloem, Andries C., Mutis, Tuna, Lokhorst, Henk M., Sasser, A.Kate, van de Donk, Niels W.C.J.

Volltext

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab von Casneuf, Tineke, Adams, Homer C., van de Donk, Niels W.C.J., Abraham, Yann, Bald, Jaime, Vanhoof, Greet, Van der Borght, Koen, Smets, Tina, Foulk, Brad, Nielsen, Karl C., Rusbuldt, Joshua, Axel, Amy, Lysaght, Andrew, Ceulemans, Hugo, Stevenaert, Frederik, Usmani, Saad Z., Plesner, Torben, Avet-Loiseau, Herve, Nijhof, Inger, Mutis, Tuna, Schecter, Jordan M., Chiu, Christopher, Bahlis, Nizar J.

Volltext

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab von Krejcik, Jakub, Frerichs, Kris A, Nijhof, Inger S, van Kessel, Berris, van Velzen, Jeroen F, Bloem, Andries C, Broekmans, Marloes E C, Zweegman, Sonja, van Meerloo, Johan, Musters, René J P, Poddighe, Pino J, Groen, Richard W J, Chiu, Christopher, Plesner, Torben, Lokhorst, Henk M, Sasser, A Kate, Mutis, Tuna, van de Donk, Niels W C J

Volltext

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma von Overdijk, Marije B, Verploegen, Sandra, Bögels, Marijn, van Egmond, Marjolein, van Bueren, Jeroen J Lammerts, Mutis, Tuna, Groen, Richard WJ, Breij, Esther, Martens, Anton CM, Bleeker, Wim K, Parren, Paul WHI

Volltext

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design von Drent, Esther, Poels, Renée, Mulders, Manon J, van de Donk, Niels W C J, Themeli, Maria, Lokhorst, Henk M, Mutis, Tuna

Volltext

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma von Drent, Esther, Groen, Richard W J, Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, Mutis, Tuna

Volltext

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors von de Weers, Michel, Tai, Yu-Tzu, van der Veer, Michael S, Bakker, Joost M, Vink, Tom, Jacobs, Daniëlle C H, Oomen, Lukas A, Peipp, Matthias, Valerius, Thomas, Slootstra, Jerry W, Mutis, Tuna, Bleeker, Wim K, Anderson, Kenneth C, Lokhorst, Henk M, van de Winkel, Jan G J, Parren, Paul W H I

Volltext

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia von Naik, Jyoti, Themeli, Maria, de Jong-Korlaar, Regina, Ruiter, Ruud W J, Poddighe, Pino J, Yuan, Huipin, de Bruijn, Joost D, Ossenkoppele, Gert J, Zweegman, Sonja, Smit, Linda, Mutis, Tuna, Martens, Anton C M, van de Donk, Niels W C J, Groen, Richard W J

Volltext

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment von van der Schans, Jort J., van de Donk, Niels W. C. J., Mutis, Tuna

Volltext

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib von Nijhof, Inger S, Groen, Richard W J, Noort, Willy A, van Kessel, Berris, de Jong-Korlaar, Regina, Bakker, Joost, van Bueren, Jeroen J L, Parren, Paul W H I, Lokhorst, Henk M, van de Donk, Niels W C J, Martens, Anton C M, Mutis, Tuna

Volltext

Targeted Therapy With Immunoconjugates for Multiple Myeloma von Bruins, Wassilis S C, Zweegman, Sonja, Mutis, Tuna, van de Donk, Niels W C J

Volltext

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment von van der Horst, Hilma J., de Jonge, A. Vera, Hiemstra, Ida H., Gelderloos, Anne T., Berry, Daniella R. A. I., Hijmering, Nathalie J., van Essen, Hendrik F., de Jong, Daphne, Chamuleau, Martine E. D., Zweegman, Sonja, Breij, Esther C. W., Roemer, Margaretha G. M., Mutis, Tuna

Volltext

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma von Poels, Renée, Drent, Esther, Lameris, Roeland, Katsarou, Afroditi, Themeli, Maria, van der Vliet, Hans J, de Gruijl, Tanja D, van de Donk, Niels W C J, Mutis, Tuna

Volltext

Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization von van Loosdregt, Jorg, Vercoulen, Yvonne, Guichelaar, Teun, Gent, Yoony Y.J., Beekman, Jeffrey M., van Beekum, Olivier, Brenkman, Arjan B., Hijnen, Dirk-Jan, Mutis, Tuna, Kalkhoven, Eric, Prakken, Berent J., Coffer, Paul J.

Volltext

Characterization of the Toll-like receptor expression profile in human multiple myeloma cells von Abdi, Jahangir, Mutis, Tuna, Garssen, Johan, Redegeld, Frank

Volltext

Immunotherapy in myeloma: how far have we come? von Franssen, Laurens E., Mutis, Tuna, Lokhorst, Henk M., van de Donk, Niels W. C. J.

Volltext

The Connection Between Minor H Antigens and Neoantigens and the Missing Link in Their Prediction von Mutis, Tuna, Xagara, Anastasia, Spaapen, Robbert M

Volltext